hepatocellular carcinoma
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
July 30, 2025Medical Communications, Research and Development AstraZeneca, NHS, National Institute for Health and Care Excellence, Oncology, dual immunotherapy, hepatocellular carcinoma, liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its dual immunotherapy …
Lilly’s Cyramza approved in US for hepatocellular carcinoma sub-population
May 13, 2019Sales and Marketing Eli Lilly, FDA, cyramza, hepatocellular carcinoma, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyramza (ramucirumab) has received approval in the US as a …
MSD’s Keytruda chalks up FDA approval in liver cancer
November 12, 2018Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …
FDA approves first new drug for liver cancer in decade
April 28, 2017Medical Communications, Sales and Marketing Bayer, Stivarga, hepatocellular carcinoma, liver cancer
The FDA has announced that it has approved the first new treatment for hepatocellular carcinoma (HCC), a type of liver …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
